Cite
MLA Citation
Kathleen A. Iles et al.. “Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?.” American surgeon, vol. 88, no. 3, 2022, pp. 471–479. http://access.bl.uk/ark:/81055/vdc_100145536476.0x000039
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kathleen A. Iles et al.. “Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?.” American surgeon, vol. 88, no. 3, 2022, pp. 471–479. http://access.bl.uk/ark:/81055/vdc_100145536476.0x000039